rawfin.tv
Biogen Completes Apellis Acquisition for $41 Cash Plus CVR Per Share
Top Storiesstocks🟠 Score 8AI Generated

Biogen Completes Apellis Acquisition for $41 Cash Plus CVR Per Share

By rawfin.tv Markets Desk||1 min read|AI-assisted · Methodology

Biogen has finalized its acquisition of Apellis Pharmaceuticals (APLS). The deal was completed at $41 in cash plus a Contingent Value Right (CVR) per share.

BiogenApellisM&AAcquisitionHealthcare

Related Articles

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

Adidas Surges 37% to Record Q3 Profit, Lifts Full-Year Targets

stocks
EQT to Acquire Cleanaway Waste for $6.5 Billion

EQT to Acquire Cleanaway Waste for $6.5 Billion

stocks
S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

S&P 500 Breaches Key Support as AI Sell-Off Pressures Tech Sector

stocks
US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

US Chip Stocks Plunge 16% in Longest Losing Streak Since 2008

stocks